The Effect of High-Volume Walking With Visual Cues (VC) in Parkinson´s Disease (PD)

July 11, 2011 updated by: University of Iceland

The Effect of High-Volume Walking With Visual Cues on Gait in People With Parkinson´s Disease. A Randomized Controlled Trial

People with disease (PD) tend to walk with short steps, decreased velocity, and increased stride time variability. Short steps and increased variability are related to greater fall risk. In addition, concurrent performance of a cognitive task (dual-task (DT)) has marked effects on gait in people with PD which is considered to reflect an impaired automaticity of gait.

Objective: To investigate short and long term effects of high-volume walking with visual spatial cues (VSC) on gait variables, automaticity, and functional mobility, in people with Parkinson´s Disease (PD), compared with walking without VSC.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Iceland
      • Mosfellsbaer, Iceland, 270
        • Reykjalundur Rehabilitation Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 75 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • a confirmed diagnosis of PD according to the UK Parkinson´s Disease Society Brain Bank Clinical Diagnostic Criteria (18)
  • <80 years of age
  • community residing
  • Hoehn and Yahr (HY) stage 2-3
  • Mini Mental State Examination (MMSE) score of >23
  • ability to walk without walking aids for a total of 20 minutes over a 30-minute period

Exclusion Criteria:

  • major modifications of Parkinson´s medication (Madopar >200 mg/d or >20% increase in Dopamine agonists) 3 weeks prior to baseline assessment
  • comorbidities or disabilities, which might influence walking
  • a history of brain surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Walking with visual cues
Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
Other: Visual Cues
Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
Active Comparator: Walking without visual cues
Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4 times a week for 4 weeks.
Other: Walking without visual cues
Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in Step Length
Time Frame: Before, after and 3 months after a 4 week training period
Before, after and 3 months after a 4 week training period
Change in Gait Velocity
Time Frame: Before, after and 3 months after a 4 week training period
Before, after and 3 months after a 4 week training period
Change in Stride Time Variability
Time Frame: Before, after and 3 months after a 4 week training period
Before, after and 3 months after a 4 week training period

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in Timed Up & Go (seconds)
Time Frame: Before, after and 3 months after a 4 week training period
Before, after and 3 months after a 4 week training period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Iceland

Collaborators

The Icelandic Parkinson´s Association.
Icelandic Physiotherapy Association

Investigators

  • Principal Investigator: Andri T Sigurgeirsson, M.Sc., University of Iceland / Reykjalundur Rehabilitation Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2008

Primary Completion (Actual)

September 1, 2008

Study Completion (Actual)

September 1, 2008

Study Registration Dates

First Submitted

July 7, 2011

First Submitted That Met QC Criteria

July 11, 2011

First Posted (Estimate)

July 12, 2011

Study Record Updates

Last Update Posted (Estimate)

July 12, 2011

Last Update Submitted That Met QC Criteria

July 11, 2011

Last Verified

March 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 123SmOkE

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson´s Disease

Clinical Trials on Visual Cues

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe